Hoimes, C. J., Galsky, M. D., Valderrama, B. P., Maruzzo, M., Font, A., Ciuleanu, T., Chatzkel, J. A., Koie, T., Puente, J., Zakharia, Y., Rosenbaum, E., Boehm, K., Loriot, Y., Bedke, J., Wirtz, H., Mihm, M., Huang, Q., Rogiers, A., Moreno, B. H., Lista, A. G. D. L. (2026). Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab for participants with muscle-invasive bladder cancer who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.4614